APOBEC3A is a prominent cytidine deaminase in breast cancer

80Citations
Citations of this article
93Readers
Mendeley users who have this article in their library.

Abstract

APOBEC cytidine deaminases are the second-most prominent source of mutagenesis in sequenced tumors. Previous studies have proposed that APOBEC3B (A3B) is the major source of mutagenesis in breast cancer (BRCA). We show that APOBEC3A (A3A) is the only APOBEC whose expression correlates with APOBEC-induced mutation load and that A3A expression is responsible for cytidine deamination in multiple BRCA cell lines. Comparative analysis of A3A and A3B expression by qRT-PCR, RSEM-normalized RNA-seq, and unambiguous RNA-seq validated the use of RNA-seq to measure APOBEC expression, which indicates that A3A is the primary correlate with APOBEC-mutation load in primary BRCA tumors. We also demonstrate that A3A has >100-fold more cytidine deamination activity than A3B in the presence of cellular RNA, likely explaining why higher levels of A3B expression contributes less to mutagenesis in BRCA. Our findings identify A3A as a major source of cytidine deaminase activity in breast cancer cells and possibly a prominent contributor to the APOBEC mutation signature.

Cite

CITATION STYLE

APA

Cortez, L. M., Brown, A. L., Dennis, M. A., Collins, C. D., Brown, A. J., Mitchell, D., … Roberts, S. A. (2019). APOBEC3A is a prominent cytidine deaminase in breast cancer. PLoS Genetics, 15(12). https://doi.org/10.1371/journal.pgen.1008545

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free